Lamivudine 300 MG

DRUG7 trials

Sponsors

University of North Carolina, Chapel Hill, Fundacion Clinic per a la Recerca Biomédica, University Hospital Virgen de las Nieves, Fundacion IDEAA, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Conditions

Acute HIV InfectionHIVHIV-1-infectionHivMild Cognitive ImpairmentRetinal DetachmentRhegmatogenous Retinal DetachmentSolid Organ Transplant

Early Phase 1

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

TerminatedNCT06056596

University of Wisconsin, MadisonRetinal Detachment, Rhegmatogenous Retinal Detachment

Start: 2024-01-30End: 2024-09-06Updated: 2024-09-19

Phase 2

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Active, not recruitingNCT06519357

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaMild Cognitive Impairment

Start: 2024-10-28End: 2026-03-31Updated: 2025-12-04

Phase 4

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

CompletedNCT03360682

Fundacion Clinic per a la Recerca BiomédicaHIV-1-infection, Solid Organ Transplant

Start: 2018-04-13End: 2020-05-21Updated: 2025-09-30

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

CompletedNCT04549467

Fundacion IDEAAHiv, HIV-1-infection

Start: 2020-11-17End: 2023-09-30Updated: 2024-02-21

Unknown Phase

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

CompletedNCT02384395

University of North Carolina, Chapel HillAcute HIV Infection, HIV

Start: 2015-09-30End: 2021-09-17Updated: 2021-11-22

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

CompletedNCT04002323

University Hospital Virgen de las NievesHIV-1-infection

Start: 2019-05-07End: 2022-03-31Updated: 2024-07-10

REal-Life Cohort With DOlutegravir + LAmivudina

CompletedNCT04638686

Instituto de Investigación Sanitaria de la Fundación Jiménez DíazHIV-1-infection

Start: 2020-06-15End: 2022-03-31Updated: 2023-11-14

Related Papers

Dolutegravir-based Antiretroviral Therapy in People With HIV With Solid Organ Transplantation: A Single-arm Pilot Clinical Trial (DTG-SOT)

Open Forum Infectious Diseases2025-03-122 citations

Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.

2025-01-151 citations